Tracy Ann Williams

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3539095/publications.pdf

Version: 2024-02-01

71 papers	5,123 citations	101535 36 h-index	88628 70 g-index
72 all docs	72 docs citations	72 times ranked	3296 citing authors

#	Article	IF	Citations
1	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	11.4	595
2	Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology,the, 2018, 6, 41-50.	11.4	582
3	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	2.7	248
4	Prevalence, Clinical, and Molecular Correlates of KCNJ5 Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	2.7	246
5	KCNJ5 Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. Hypertension, 2012, 59, 235-240.	2.7	176
6	Sustained recruitment of phospholipase C-Î³ to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene, 2000, 19, 1509-1518.	5.9	154
7	Somatic ATP1A1 , ATP2B3 , and KCNJ5 Mutations in Aldosterone-Producing Adenomas. Hypertension, 2014, 63, 188-195.	2.7	151
8	Cloning and Expression of an Evolutionary Conserved Single-domain Angiotensin Converting Enzyme from Drosophila melanogaster. Journal of Biological Chemistry, 1995, 270, 13613-13619.	3.4	131
9	Effect ofKCNJ5Mutations on Gene Expression in Aldosterone-Producing Adenomas and Adrenocortical Cells. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1567-E1572.	3.6	130
10	Prevalence and Characteristics of Familial Hyperaldosteronism. Hypertension, 2011, 58, 797-803.	2.7	128
11	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. Hypertension, 2016, 67, 139-145.	2.7	127
12	International Histopathology Consensus for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 42-54.	3.6	127
13	Mass Spectrometryâ€“Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. Clinical Chemistry, 2016, 62, 514-524.	3.2	123
14	Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. Clinica Chimica Acta, 2017, 470, 115-124.	1.1	116
15	Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Molecular and Cellular Endocrinology, 2015, 411, 146-154.	3.2	115
16	Role of KCNJ5 in familial and sporadic primary aldosteronism. Nature Reviews Endocrinology, 2013, 9, 104-112.	9.6	101
17	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	2.7	94
18	MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. European Journal of Endocrinology, 2018, 179, R19-R29.	3.7	89

#	Article	IF	Citations
19	A Novel Y152C KCNJ5 Mutation Responsible for Familial Hyperaldosteronism Type III. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1861-E1865.	3.6	86
20	The Drosophila melanogaster-related angiotensin-I-converting enzymes Acer and Ance . Distinct enzymic characteristics and alternative expression during pupal development. FEBS Journal, 1998, 257, 599-606.	0.2	78
21	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	2.7	77
22	Substrate Dependence of Angiotensin I-Converting Enzyme Inhibition: Captopril Displays a Partial Selectivity for Inhibition ofN-Acetyl-Seryl-Aspartyl-Lysyl-Proline Hydrolysis Compared with That of Angiotensin I^{Â·}. Molecular Pharmacology, 1997, 51, 1070-1076.	2.3	68
23	Glucocorticoid Remediable Aldosteronism: Low Morbidity and Mortality in a Four-Generation Italian Pedigree. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3187-3191.	3.6	67
24	LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. Atherosclerosis, 2009, 207, 38-44.	0.8	64
25	Visinin-Like 1 Is Upregulated in Aldosterone-Producing Adenomas With KCNJ5 Mutations and Protects From Calcium-Induced Apoptosis. Hypertension, 2012, 59, 833-839.	2.7	64
26	A Peptide Representing the Carboxyl-terminal Tail of the Met Receptor Inhibits Kinase Activity and Invasive Growth. Journal of Biological Chemistry, 1999, 274, 29274-29281.	3.4	59
27	A Case of Severe Hyperaldosteronism Caused by a De Novo Mutation Affecting a Critical Salt Bridge Kir3.4 Residue. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E114-E118.	3.6	53
28	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 650-657.	2.7	51
29	Is Primary Aldosteronism Still Largely Unrecognized?. Hormone and Metabolic Research, 2017, 49, 908-914.	1.5	50
30	Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. Journal of Human Hypertension, 2004, 18, 47-51.	2.2	49
31	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3706-e3717.	3.6	47
32	Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. Molecular and Cellular Endocrinology, 2015, 399, 311-320.	3.2	45
33	Teratocarcinoma-Derived Growth Factor-1 Is Upregulated in Aldosterone-Producing Adenomas and Increases Aldosterone Secretion and Inhibits Apoptosis In Vitro. Hypertension, 2010, 55, 1468-1475.	2.7	43
34	DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?. European Journal of Endocrinology, 2018, 178, R1-R9.	3.7	39
35	ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. Journal of Human Hypertension, 2016, 30, 374-378.	2.2	38
36	Familial hyperaldosteronism type III. Journal of Human Hypertension, 2017, 31, 776-781.	2.2	37

#	Article	IF	Citations
37	Characterization of Neuronal and Endothelial Forms of Angiotensin Converting Enzyme in Pig Brain. Journal of Neurochemistry, 1991, 57, 193-199.	3.9	36
38	Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism. Hypertension, 2017, 70, 875-881.	2.7	35
39	Single-Center Prospective Cohort Study on the Histopathology, Genotype, and Postsurgical Outcomes of Patients With Primary Aldosteronism. Hypertension, 2021, 78, 738-746.	2.7	35
40	KCNJ5 Mutations Are the Most Frequent Genetic Alteration in Primary Aldosteronism. Hypertension, 2015, 65, 507-509.	2.7	34
41	Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney International, 2005, 67, 631-637.	5.2	33
42	Disordered CYP11B2 Expression in Primary Aldosteronism. Hormone and Metabolic Research, 2017, 49, 957-962.	1.5	31
43	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 274-282.	2.5	28
44	Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. Pharmacogenomics, 2014, 15, 1643-1652.	1.3	27
45	Primary Aldosteronism. Hypertension, 2019, 74, 809-816.	2.7	27
46	The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2027-e2036.	3.6	27
47	1Î±,25-Dihydroxyvitamin D3 inhibits the human H295R cell proliferation by cell cycle arrest: A model for a protective role of vitamin D receptor against adrenocortical cancer. Journal of Steroid Biochemistry and Molecular Biology, 2014, 140, 26-33.	2.5	26
48	Blood Pressure in Patients with Primary Aldosteronism Is Influenced by Bradykinin B2 Receptor and Â-Adducin Gene Polymorphisms. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3337-3343.	3.6	26
49	METPRC mutations in the ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential. , 1999, 181, 507-514.		24
50	Renin and Aldosterone Measurements in the Management of Arterial Hypertension. Hormone and Metabolic Research, 2015, 47, 418-426.	1.5	24
51	Toward a Role for Angiotensin-Converting Enzyme in Insects. Annals of the New York Academy of Sciences, 1998, 839, 288-292.	3.8	21
52	A study of chimeras constructed with the two domains of angiotensin I-converting enzyme. Biochemical Pharmacology, 1996, 51, 11-14.	4.4	18
53	Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Molecular and Cellular Endocrinology, 2012, 355, 162-168.	3.2	18
54	KCNJ5 Mutations: Sex, Salt and Selection. Hormone and Metabolic Research, 2015, 47, 953-958.	1.5	18

#	Article	IF	Citations
55	Diverse Responses of Autoantibodies to the Angiotensin II Type 1 Receptor in Primary Aldosteronism. Hypertension, 2019, 74, 784-792.	2.7	17
56	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	3.6	17
57	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1708-1716.	3.6	16
58	A genetic study of angiotensin I-converting enzyme levels in human semen. Molecular and Cellular Endocrinology, 1995, 107, 215-219.	3.2	15
59	Is Familial Hyperaldosteronism Underdiagnosed in Hypertensive Children?. Hypertension, 2011, 57, 1053-1055.	2.7	15
60	Steroid Hormone Production in Patients with Aldosterone Producing Adenomas. Hormone and Metabolic Research, 2015, 47, 967-972.	1.5	14
61	Pathophysiology and histopathology of primary aldosteronism. Trends in Endocrinology and Metabolism, 2022, 33, 36-49.	7.1	14
62	Recent Developments in Primary Aldosteronism. Experimental and Clinical Endocrinology and Diabetes, 2016, 124, 335-341.	1.2	11
63	Bradykinin B2Receptor Gene C-58T Polymorphism and Insulin Resistance. A Study on Obese Patients. Hormone and Metabolic Research, 2004, 36, 243-246.	1.5	10
64	Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. Hypertension, 2015, 66, 248-253.	2.7	10
65	Primary aldosteronism (PA) and endothelial progenitor cell (EPC) bioavailability. Clinical Endocrinology, 2008, 69, 528-534.	2.4	9
66	Aldosterone does not Modify Gene Expression in Human Endothelial Cells. Hormone and Metabolic Research, 2012, 44, 234-238.	1.5	9
67	A Particular Phenotype in a Girl with Aldosterone Synthase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3168-3172.	3.6	8
68	Subtype Diagnosis of Primary Aldosteronism: Approach to Different Clinical Scenarios. Hormone and Metabolic Research, 2015, 47, 959-966.	1.5	8
69	Integration of artificial intelligence and plasma steroidomics with laboratory information management systems: application to primary aldosteronism. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1929-1937.	2.3	6
70	Assessing outcomes after adrenalectomy for unilateral primary aldosteronism. Surgery, 2019, 166, 1199-1200.	1.9	4
71	Histopathology and Genetic Causes of Primary Aldosteronism in Young Adults. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2473-2482.	3.6	4